- Home
- CGEN
CGEN
Compugen Ltd.
as of 05-13-2026 3:36pm EST
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
Upcoming Earnings Alert:
Get ready for potential market movements as Compugen Ltd. (CGEN) prepares to release earnings report on 18 May 2026.
| Founded: | 1993 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 270.4M | IPO Year: | 2001 |
| Target Price: | $5.00 | AVG Volume (30 days): | 518.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $1.29 - $3.23 | Next Earning Date: | 05-18-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | -74.12% | Revenue Growth (next year): | 75.09% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | -36.69% |
AI-Powered CGEN Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Compugen Ltd. (CGEN)
SVP, Business Development
Avg Cost/Share
$3.20
Shares
2,000
Total Value
$6,400.00
Owned After
29,375
SEC Form 4
President and CEO
Avg Cost/Share
$3.20
Shares
5,000
Total Value
$16,000.50
Owned After
11,375
SEC Form 4
SVP, Business Development
Avg Cost/Share
$2.80
Shares
2,000
Total Value
$5,600.00
Owned After
29,375
SEC Form 4
President and CEO
Avg Cost/Share
$2.90
Shares
5,000
Total Value
$14,521.00
Owned After
11,375
SEC Form 4
SVP, Business Development
Avg Cost/Share
$2.56
Shares
3,125
Total Value
$8,012.50
Owned After
29,375
SEC Form 4
SVP, Business Development
Avg Cost/Share
$2.42
Shares
5,375
Total Value
$13,007.50
Owned After
29,375
SEC Form 4
SVP, Business Development
Avg Cost/Share
$2.30
Shares
2,500
Total Value
$5,750.00
Owned After
29,375
SEC Form 4
SVP, Business Development
Avg Cost/Share
$2.04
Shares
11,875
Total Value
$24,187.00
Owned After
29,375
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Levine Zurit | CGEN | SVP, Business Development | Apr 24, 2026 | Sell | $3.20 | 2,000 | $6,400.00 | 29,375 | |
| Ophir Eran | CGEN | President and CEO | Apr 24, 2026 | Sell | $3.20 | 5,000 | $16,000.50 | 11,375 | |
| Levine Zurit | CGEN | SVP, Business Development | Apr 14, 2026 | Sell | $2.80 | 2,000 | $5,600.00 | 29,375 | |
| Ophir Eran | CGEN | President and CEO | Apr 14, 2026 | Sell | $2.90 | 5,000 | $14,521.00 | 11,375 | |
| Levine Zurit | CGEN | SVP, Business Development | Apr 10, 2026 | Sell | $2.56 | 3,125 | $8,012.50 | 29,375 | |
| Levine Zurit | CGEN | SVP, Business Development | Apr 8, 2026 | Sell | $2.42 | 5,375 | $13,007.50 | 29,375 | |
| Levine Zurit | CGEN | SVP, Business Development | Apr 7, 2026 | Sell | $2.30 | 2,500 | $5,750.00 | 29,375 | |
| Levine Zurit | CGEN | SVP, Business Development | Mar 26, 2026 | Sell | $2.04 | 11,875 | $24,187.00 | 29,375 |
Compare CGEN vs Leading Stocks
See how CGEN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CGEN Compugen Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.